// App-Quantinova.ai

: Subcutaneous tanezumab 2.5 MG or 5 MG for patients with osteoarthritis of the knee or hip: onset and maintenance of efficacy over 24 weeks

Researchers

Presenter

  • F. Berenbaum

Principal Investigators

  • R. Langford

  • S. Perrot

  • K. Miki

  • F.J. Blanco

  • T. Yamabe

  • N. Isogawa

  • S. Araki

  • R. Junor

  • W. Carey

  • L. Viktrup

  • C.R. West

  • M.T. Brown

  • K. Verburg

Medical Centers

  • Sorbonne Université, INSERM, AP-HP Hospital Saint Antoine, Paris, France,

  • Guy's Hospital, London, United Kingdom

  • Paris Descartes University, Paris, France

  • Osaka Yukioka Coll. of Hlth.Sci., Hayaishi Hosp., Osaka, Japan

  • INIBC-Complejo Hosp.ario Univ.rio A Coruña, Departamento of Med., Univ. de A Coruña, La Coruña, Spain

  • Pfizer Inc, Groton, CT, USA,

  • Pfizer Japan, Tokyo, Japan

  • Pfizer Inc., Tadworth, United Kingdom

  • Eli Lilly and Company, Indianapolis, IN

Locations

  • France

  • United Kingdom

  • Japan

  • Spain

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoarthritis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved